Testing High-Impact Exercise for Men with Prostate Cancer That Has Spread to Bone
Tests a brief, bone-loading exercise program in adult men with prostate cancer spread to bones.
Plain-language title generated from the registry record
Registry title: High Impact Training to Patients with Prostate Cancer and Bone Metastases
Key facts
- Where
- Herlev, DenmarkSee the site
Where in Denmark
- Herlev and Gentofte HospitalHerlev, DenmarkTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Copenhagen University Hospital at Herlev
- Trial code
- NCT06259279
- Record updated
- 13 February 2025
- Original description
HIP is a randomized controlled trial. The aim is investigate the effect, safety and feasibility of brief, high-impact exercise targeting bones in patients with prostate cancer and bone metastases. Furthermore, to investigate the effects of the intervention on bone status (bone mineral density) and body composition, physical function and performance, patient reported quality-of-life outcomes, falls and hospitalizations. The effects of resistance training on the antitumor immunity will be assessed in the peripheral blood and tumor biopsies (HIPimmune).Read full original descriptionShow less
High Impact Training to Patients with Prostate Cancer and Bone Metastases
HIP is a randomized controlled trial. The aim is investigate the effect, safety and feasibility of brief, high-impact exercise targeting bones in patients with prostate cancer and bone metastases. Furthermore, to investigate the effects of the intervention on bone status (bone mineral density) and body composition, physical function and performance, patient reported quality-of-life outcomes, falls and hospitalizations. The effects of resistance training on the antitumor immunity will be assessed in the peripheral blood and tumor biopsies (HIPimmune).
Inclusion: Patients with metastatic hormone sensitive prostate cancer (mHSPC); Patients must have bone metastases according to the most recent imaging (Bone scan, CT, MRI and/or PET); Patients must be treated with androgen deprivation therapy (ADT) (orchiectomy, luteinizing hormone-releasing hormone (LHRH) agonist or antagonist treatment) started < 12 months ago. Additional treatment in the mHSPC setting, i.e., radiotherapy (RT) of the prostate, novel hormone agents (NHA) and/or docetaxel is permitted; Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status score <2; Patients must be able to speak and read Danish and provide a signed informed consent form; Patients must be ambulatory without walking aids.
Exclusion: Patients with planned or prior palliative radiation therapy to the bone; Patients with major surgery within the past 6 months; HIPimmune: all patients included in HIP are eligible for HIPimmune; Patients with any physical condition that interferes with the performance of physical exercise training; Patients with presence of any musculoskeletal, cardiovascular, or neurologic conditions that may prevent patients from exercising; Patients with bone pain requiring opioids.